Opiant Pharmaceuticals, Inc. (OPNT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
233 Wilshirre Boulevard
Santa Monica, CA 90401
United States of America (the)
Phone
310 598 5410
Website
Sector
Healthcare
Industry
Biotechnology
Employees
37
First IPO Date
June 04, 2007
| Name | Title | Pay | Year Born |
| Roger Crystal | Pres, Chief Executive Officer & Director | 1.01M | 1976 |
| David D. O'Toole | Chief Financial Officer | 624,739 | 1959 |
| Phillip Skolnick | Chief Scientific Officer | 638,175 | 1947 |
| Brian Gorman | EVice President Corporation Devel. & Gen. Counsel | 0 | N/A |
| Matthew R. Ruth | Chief Commercial Officer | 0 | 1970 |
| Mark Heath Ellison | Chief Devel. Officer | 0 | N/A |
| Ben Atkins | Vice President of Communications & Investor Relations | 0 | N/A |
Opiant Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on inventing remedies for both various addictions and drug overdoses. A key product in their current portfolio is NARCAN nasal spray, which provides a critical solution for counteracting opioid overdoses. Their development pipeline is robust, featuring several promising drug candidates designed to address further opioid overdose reversal needs, alcohol use disorders, acute cannabinoid overdose, and opioid use disorders. The company, which established itself in 2005, was initially named Lightlake Therapeutics Inc. before rebranding as Opiant Pharmaceuticals, Inc. in January 2016. Its corporate headquarters are located in Santa Monica, California.